Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
April 10, 2026 17:02 ET | Source: Replimune, Inc. WOBURN, Mass., April…
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
October 19, 2025 08:00 ET | Source: Replimune, Inc. WOBURN, Mass., Oct.…
